Iryna Yaryhina: Moving Beyond Episomal Fixes Toward Genomic Durability for Hemophilia
Iryna Yaryhina, Research Engineer at Pharmaceutical company «Zdorovye», shared on LinkedIn about a recent article by Nishal Kumarasamy et al, published in :
”Gene Editing for Hemophilia: Moving Beyond Episomal Fixes Toward Genomic Durability
Most approved gene therapies for hemophilia rely on AAV-mediated gene addition.
This approach works, but it remains limited by episomal expression, immune responses, and declining durability, especially for FVIII.
In a recent Frontiers in Bioengineering and Biotechnology review, ‘Exploring gene editing as a potential therapeutic strategy for hemophilia,’ the authors provide a systematic overview of how genome editing aims to address these fundamental constraints.
Instead of adding a functional gene copy, gene editing directly modifies the genome.
The goal is mutation correction, stable integration, or rebalancing of coagulation pathways.
Key highlights:
- A comparative analysis of ZFNs, TALENs, and CRISPR/Cas9, with clear discussion of efficiency, specificity, and translational readiness.
- Multiple editing strategies, including HDR and NHEJ, safe-harbour integration (albumin, AAVS1, H11), and direct correction of F8 and F9.
- The rise of base editing and prime editing for precise, double-strand-break–free correction of point mutations.
- AAV–LNP hybrid delivery approaches and CRISPR-based rebalancing strategies targeting anticoagulant pathways such as antithrombin.
- Early in vivo CRISPR clinical trials for hemophilia B, signalling a shift toward potentially permanent genomic correction.
Why this matters:
Hemophilia exposes a core limitation of classical gene therapy.
Expression without genomic integration rarely translates into long-term durability.
Genome editing reframes treatment as cell-heritable correction, while introducing new engineering constraints related to delivery, immune compatibility, and long-term safety.
Importantly, this review does not oversell the technology.
It maps the real biological and translational bottlenecks that will determine whether gene editing becomes clinically transformative or remains largely preclinical.”
Title: Exploring gene editing as a potential therapeutic strategy for hemophilia
Authors: Nishal Kumarasamy, Balaji Balakrishnan
Read the Full Article on Frontiers
Stay updated on all scientific advances with Hemostasis Today.
-
May 28, 2026, 09:16Maxime Dely: The Human Connection Behind Stem Cell Donation
-
May 28, 2026, 09:15Heghine Khachatryan: Maternal Health Begins With Recognizing Iron Deficiency Early
-
May 28, 2026, 09:15Alejandro González Veliz: Why Cardiovascular Prevention Matters More Than Intervention
-
May 28, 2026, 05:29Kidist K.: First Balloon Pulmonary Angioplasty Performed as New CTEPH Program Launches
-
May 28, 2026, 04:59Maria Sol Andres: Exploring Lipid Disorders in Modern Cancer Care
-
May 28, 2026, 04:42Francesca Granata: Representing the Porphyria Community at the 79th World Health Assembly
-
May 28, 2026, 04:29Samone Cook: When Collaboration Turns Into Organizational Coagulation
-
May 28, 2026, 03:42Lara Bloom: 15,000 Steps, Countless Conversations – One Unforgettable WHA79
-
May 27, 2026, 23:00Octavio Marques Pontes-Neto: Exchanging Latin American Experiences at the Global Stroke Alliance Meeting in Buenos Aires